Weekly Digest - November 2026

Weekly Digest - November 2026

09 November 2026: iDEL Therapeutics and Daiichi Sankyo partner to develop targeted Multi-Drug Conjugate for Solid tumors

  • iDEL Therapeutics has entered a multi-year global research collaboration with Daiichi Sankyo to evaluate a novel multi-drug conjugate using iDEL’s synthetic shuttle platform for selected solid tumor indications. The collaboration will focus on preclinical development, with research conducted by iDEL and scientists at Daiichi Sankyo’s Research Institute Munich
  • The research will directly compare the MDC approach with an ADC carrying a comparable payload, aiming to evaluate whether the synthetic shuttle can improve intracellular drug delivery. Financial terms, development milestones, specific tumor indications and the identity of the payloads have not been disclosed
  • The collaboration addresses a key limitation of conventional ADCs, inefficient intracellular drug delivery due to endosomal entrapment. Following cellular uptake, ADC payloads can become trapped or degraded within endosomes, potentially limiting the amount of active drug reaching its intracellular target
  • iDEL’s synthetic shuttle technology is designed to transport therapeutic payloads directly into the tumor-cell cytosol, bypassing endosomal trapping and enabling delivery of diverse payloads, including small molecules, peptides and single-domain antibodies (VHHs)
  • Strategically, the collaboration provides Daiichi Sankyo an opportunity to explore a differentiated conjugate modality beyond conventional ADC architecture, while validating iDEL’s platform through a comparative preclinical partnership with an established ADC developer. If successful, the approach could potentially address intracellular delivery limitations and expand access to previously difficult-to-target intracellular cancer drivers

For full story click  here

Share this